IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 267 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.49 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,405,078 | -33.7% | 299,885 | +22.6% | 0.01% | -47.8% |
| Q1 2024 | $3,625,209 | +1245.2% | 244,616 | +638.0% | 0.02% | +1050.0% |
| Q4 2023 | $269,493 | -66.8% | 33,148 | -71.2% | 0.00% | -80.0% |
| Q2 2023 | $811,550 | +231110.8% | 115,277 | +100.4% | 0.01% | +100.0% |
| Q1 2023 | $351 | -42.0% | 57,527 | -39.2% | 0.01% | -58.3% |
| Q4 2022 | $605 | -99.9% | 94,629 | +20.1% | 0.01% | -25.0% |
| Q3 2022 | $755,000 | -24.4% | 78,780 | -12.9% | 0.02% | -38.5% |
| Q2 2022 | $999,000 | +97.4% | 90,494 | +198.0% | 0.03% | +116.7% |
| Q1 2022 | $506,000 | -69.7% | 30,370 | -65.3% | 0.01% | -57.1% |
| Q4 2021 | $1,671,000 | +41.3% | 87,532 | +82.4% | 0.03% | +47.4% |
| Q3 2021 | $1,183,000 | -75.1% | 47,982 | -68.0% | 0.02% | -80.0% |
| Q1 2021 | $4,752,000 | +441.8% | 150,091 | +369.9% | 0.10% | +120.9% |
| Q2 2020 | $877,000 | +496.6% | 31,938 | +68.1% | 0.04% | +975.0% |
| Q3 2017 | $147,000 | – | 19,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 3,019,201 | $26,720,000 | 20.38% |
| Broadfin Capital, LLC | 5,951,153 | $52,668,000 | 6.92% |
| GREAT POINT PARTNERS LLC | 5,567,348 | $49,271,000 | 6.23% |
| Avoro Capital Advisors LLC | 10,261,039 | $90,810,000 | 5.43% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $19,367,000 | 5.00% |
| Prosight Management, LP | 1,062,500 | $9,403,000 | 4.85% |
| Perceptive Advisors | 12,241,111 | $108,333,000 | 4.12% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,850,000 | 3.21% |
| QVT Financial LP | 1,021,361 | $8,696,000 | 2.84% |
| Vivo Capital, LLC | 1,600,000 | $14,160,000 | 1.81% |